Stock
GSK plc American Depositary Shares (Each representing two Ordinary Shares) GSK
Overview
GSK market data
Price History
GSK price chart
Valuation & Profitability
- P/E (TTM)
- 13.13 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 367.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1,361.00 – $2,282.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $76.5K · P/B 4.51 · P/S 2.33.
Company news
GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled SyringeBenzinga · Jul 24, 2026, 3:30 PM
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of ScheduleBenzinga · Jul 22, 2026, 5:39 PM
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung CancerBenzinga · Jul 22, 2026, 4:41 PM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.Benzinga · Jul 17, 2026, 5:29 PM
Disappointing Data Prompts GSK to Drop Cough Drug DevelopmentBenzinga · Jul 17, 2026, 2:48 PM
GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical TrialsBenzinga · Jul 17, 2026, 11:44 AM
American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus NephritisGlobenewswire Inc · Jul 16, 2026, 3:15 PM